Thinking "Beyond the Pill" - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Thinking "Beyond the Pill"

Pharma is under a lot of pressure to demonstrate the value of their medicines. As Jerry Cacciotti, partner of the consultancy firm, Oliver Wyman, stressed in a press statement, today’s payers are now focussing more on value and want to see better outcomes with lower costs.

This month, healthcare leaders from six of the world’s top 20 pharmaceutical companies met together in collaboration with the Oliver Wyman Health Innovation Center to explore the industry’s changing role. It was agreed that pharma needs to look beyond the pill and find new ways to drive value in the healthcare system. It is, however, unclear how pharma fits into the new value-based structure and the idea of the meeting was mainly to get pharma leaders and healthcare innovators together to discuss new ways of working together towards accessing the value of the “pill plus” solutions.

According to a research by Oliver Wyman, which was released during the meeting, pharma is heavily investing its R&D budgets in niche cancers and rare disease drugs for complex disease. To sustain a 5% growth, the industry would need to bring 1500 drugs into the market, which is five times the rate of new therapies being launched, noted Cacciotti. As this is unlikely to happen, he said that pharma companies would, therefore, need to find ways to coordinate with value-based healthcare across the whole spectrum of diseases.

Another meeting has been scheduled in 2014 where the same group of leaders will discuss legal and regulatory issues related to potential new pharma business designs.

Source: Oliver Wyman


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here